Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, comparative trial on the effect of febuxostat in preventing cerebral and cardiorenovascular events in patients with hyperuricemia

Next Previous
Trial Profile

A multicenter, randomized, comparative trial on the effect of febuxostat in preventing cerebral and cardiorenovascular events in patients with hyperuricemia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Febuxostat (Primary) ; Allopurinol
  • Indications Cardiovascular disorders; Cerebrovascular disorders; Hyperuricaemia; Kidney disorders; Vascular disorders
  • Focus Therapeutic Use
  • Acronyms FREED

    • Most Recent Events

    • 15 Feb 2022 Results of a subgroup analysis assessing the outcomes in patients with and without a history of cardiovascular disease will be published in the International Journal of Cardiology
    • 04 Oct 2021 Results of post-hoc analysis assessing optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks, published in the Rheumatology.
    • 07 Mar 2019 Primary endpoint of development of cerebral or cardiovascular events and all deaths has been met, according to results published in the European Heart Journal.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top